These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
604 related articles for article (PubMed ID: 15007088)
1. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. Innocenti F; Undevia SD; Iyer L; Chen PX; Das S; Kocherginsky M; Karrison T; Janisch L; Ramírez J; Rudin CM; Vokes EE; Ratain MJ J Clin Oncol; 2004 Apr; 22(8):1382-8. PubMed ID: 15007088 [TBL] [Abstract][Full Text] [Related]
2. Clinical observations on associations between the UGT1A1 genotype and severe toxicity of irinotecan. Lu YY; Huang XE; Wu XY; Cao J; Liu J; Wang L; Xiang J Asian Pac J Cancer Prev; 2014; 15(7):3335-41. PubMed ID: 24815493 [TBL] [Abstract][Full Text] [Related]
3. The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity. Ramchandani RP; Wang Y; Booth BP; Ibrahim A; Johnson JR; Rahman A; Mehta M; Innocenti F; Ratain MJ; Gobburu JV J Clin Pharmacol; 2007 Jan; 47(1):78-86. PubMed ID: 17192505 [TBL] [Abstract][Full Text] [Related]
4. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. Stewart CF; Panetta JC; O'Shaughnessy MA; Throm SL; Fraga CH; Owens T; Liu T; Billups C; Rodriguez-Galindo C; Gajjar A; Furman WL; McGregor LM J Clin Oncol; 2007 Jun; 25(18):2594-600. PubMed ID: 17577039 [TBL] [Abstract][Full Text] [Related]
5. UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan. Hazama S; Mishima H; Tsunedomi R; Okuyama Y; Kato T; Takahashi K; Nozawa H; Ando H; Kobayashi M; Takemoto H; Nagata N; Kanekiyo S; Inoue Y; Hamamoto Y; Fujita Y; Hinoda Y; Okayama N; Oba K; Sakamoto J; Oka M Cancer Sci; 2013 Dec; 104(12):1662-9. PubMed ID: 24033692 [TBL] [Abstract][Full Text] [Related]
6. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Innocenti F; Grimsley C; Das S; Ramírez J; Cheng C; Kuttab-Boulos H; Ratain MJ; Di Rienzo A Pharmacogenetics; 2002 Dec; 12(9):725-33. PubMed ID: 12464801 [TBL] [Abstract][Full Text] [Related]
7. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. Innocenti F; Kroetz DL; Schuetz E; Dolan ME; Ramírez J; Relling M; Chen P; Das S; Rosner GL; Ratain MJ J Clin Oncol; 2009 Jun; 27(16):2604-14. PubMed ID: 19349540 [TBL] [Abstract][Full Text] [Related]
8. An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients. Ichikawa W; Uehara K; Minamimura K; Tanaka C; Takii Y; Miyauchi H; Sadahiro S; Fujita K; Moriwaki T; Nakamura M; Takahashi T; Tsuji A; Shinozaki K; Morita S; Ando Y; Okutani Y; Sugihara M; Sugiyama T; Ohashi Y; Sakata Y Br J Cancer; 2015 May; 112(10):1709-16. PubMed ID: 25880011 [TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene and irinotecan toxicity. Kitagawa C; Ando M; Ando Y; Sekido Y; Wakai K; Imaizumi K; Shimokata K; Hasegawa Y Pharmacogenet Genomics; 2005 Jan; 15(1):35-41. PubMed ID: 15864124 [TBL] [Abstract][Full Text] [Related]
10. UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients. Gao J; Zhou J; Li Y; Lu M; Jia R; Shen L Med Oncol; 2013; 30(3):604. PubMed ID: 23686699 [TBL] [Abstract][Full Text] [Related]
11. [Relationship between UGT1A1 gene polymorphisms and irinotecan-induced severe adverse events]. Wang XF; Ma C; Gong FF; Yi SY; Xing GC; Wang KJ; Yang Q; Cao W Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):594-599. PubMed ID: 30139029 [No Abstract] [Full Text] [Related]
12. UGT1A1*6 polymorphisms are correlated with irinotecan-induced neutropenia: a systematic review and meta-analysis. Zhang X; Yin JF; Zhang J; Kong SJ; Zhang HY; Chen XM Cancer Chemother Pharmacol; 2017 Jul; 80(1):135-149. PubMed ID: 28585035 [TBL] [Abstract][Full Text] [Related]
13. Intra-ethnic differences in genetic variants of the UGT-glucuronosyltransferase 1A1 gene in Chinese populations. Zhang A; Xing Q; Qin S; Du J; Wang L; Yu L; Li X; Xu L; Xu M; Feng G; He L Pharmacogenomics J; 2007 Oct; 7(5):333-8. PubMed ID: 17060921 [TBL] [Abstract][Full Text] [Related]
14. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Ando Y; Saka H; Ando M; Sawa T; Muro K; Ueoka H; Yokoyama A; Saitoh S; Shimokata K; Hasegawa Y Cancer Res; 2000 Dec; 60(24):6921-6. PubMed ID: 11156391 [TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer. Araki K; Fujita K; Ando Y; Nagashima F; Yamamoto W; Endo H; Miya T; Kodama K; Narabayashi M; Sasaki Y Cancer Sci; 2006 Nov; 97(11):1255-9. PubMed ID: 16965601 [TBL] [Abstract][Full Text] [Related]
16. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Iyer L; Das S; Janisch L; Wen M; Ramírez J; Karrison T; Fleming GF; Vokes EE; Schilsky RL; Ratain MJ Pharmacogenomics J; 2002; 2(1):43-7. PubMed ID: 11990381 [TBL] [Abstract][Full Text] [Related]
17. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Liu CY; Chen PM; Chiou TJ; Liu JH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Wang WS Cancer; 2008 May; 112(9):1932-40. PubMed ID: 18300238 [TBL] [Abstract][Full Text] [Related]
18. Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities. Fakih MG; Ross ME; Starostik P Clin Colorectal Cancer; 2007 Jul; 6(8):583-7. PubMed ID: 17681105 [TBL] [Abstract][Full Text] [Related]
19. UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Onoue M; Terada T; Kobayashi M; Katsura T; Matsumoto S; Yanagihara K; Nishimura T; Kanai M; Teramukai S; Shimizu A; Fukushima M; Inui K Int J Clin Oncol; 2009 Apr; 14(2):136-42. PubMed ID: 19390945 [TBL] [Abstract][Full Text] [Related]
20. [Study of irinotecan-induced toxicity and its correlation to UGT1A1 gene promoter polymorphisms]. Li H; Huang H; Liu JH Zhonghua Fu Chan Ke Za Zhi; 2011 Dec; 46(12):888-91. PubMed ID: 22333276 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]